Pancreatic Cancer Research

ResearcherWashington University in St. LouisActive in the last 2 years

Elizabeth M. Jaffee

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-3841-6549; OpenAlex author ID A5050642902; NIH RePORTER profile ID 6215429. Sources: ClinicalTrials.gov.

Their work

Papers
102 (first author 8, last author 12)
Trials
1
Grants
6
Labs led
1
Collaborators
290
Papers, trials and grants by year

2011: 3 papers · 2012: 5 papers · 2013: 8 papers · 2014: 4 papers · 2015: 5 papers, 1 grant · 2016: 4 papers · 2017: 6 papers, 1 grant · 2018: 6 papers · 2019: 5 papers · 2020: 8 papers, 1 trial · 2021: 7 papers · 2022: 6 papers, 1 grant · 2023: 2 papers · 2024: 11 papers · 2025: 7 papers, 1 grant · 2026: 15 papers, 2 grants

Papers 50 of 102

  1. Postsurgical circulating tumor DNA as a prognostic biomarker for relapse of resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.gassur.2026.102359↗
  2. Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. Co-author DOI 10.1038/s41467-026-68324-4↗
  3. The combination of a cancer vaccine, pembrolizumab, and stereotactic body radiation in patients with locally advanced pancreatic cancer: a single-arm, phase II… Co-author DOI 10.1038/s41467-026-69294-3↗
  4. Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial Co-author DOI 10.1038/s41467-026-71968-x↗
  5. Patient-derived Organoid Pharmacotyping as a Predictive Tool for Therapeutic Selection in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000006517↗
  6. Synthetic long peptide and DNA personalized cancer vaccines induce robust neoantigen-specific T cell responses in pancreatic cancer. Co-author DOI 10.1126/sciadv.aei1190↗
  7. Cancer-Associated Fibroblasts Promote Epithelial-Mesenchymal Transition and Classical to Basal Subtype Shift in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-25-0331↗
  8. First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts. Co-author DOI 10.1158/2159-8290.cd-25-2245↗
  9. Targeting RAS for Pancreatic Cancer Interception. Co-author DOI 10.1158/2159-8290.cd-26-1179↗
  10. A Randomized Phase II Study: CRS207/GVAX plus Anti-PD-1 and Anti-CTLA4 Recruits Mesothelin- and mKRAS-Specific T Cells into PDAC. Co-author DOI 10.1158/2326-6066.cir-25-0545↗
  11. Computational Modeling of Cellular Influence Delineates Functionally Relevant and Distinct Cellular Neighborhoods in Primary and Metastatic Pancreatic Ductal A… Co-author DOI 10.1158/2326-6066.cir-25-0844↗
  12. Cytometric Atlas of Combination Immunotherapy in Pancreatic Cancer: Blood-Based Signatures Reveal Vaccine and Checkpoint Inhibitor Responses. Co-author DOI 10.1158/2326-6066.cir-25-1126↗
  13. CXCR2 blockade overcomes the NETosis-mediated resistance to MEK inhibition in pancreatic cancer models. Co-author DOI 10.1172/jci196622↗
  14. Safety and immunologic impact of neoadjuvant/adjuvant GVAX, cyclophosphamide, pembrolizumab, and anti-CSF1R agent IMC-CS4 in pancreatic adenocarcinoma. Co-author DOI 10.3389/fimmu.2026.1715761↗
  15. Multimodal Machine Learning for Predicting Outcomes in the PASS-01 Trial of Systemic Therapy for Metastatic Pancreatic Cancer Co-author DOI 10.64898/2026.08.24.26360900↗
  16. Phase 1 Study of Adjuvant Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor-Transduced Pancreatic Tumor Cell Vaccine, Low-Dose Cyclophosphamide, and … Co-author DOI 10.1016/j.ijrobp.2024.10.039↗
  17. CD137 agonism enhances anti-PD1 induced activation of expanded CD8+ T cell clones in a neoadjuvant pancreatic cancer clinical trial. Co-author DOI 10.1016/j.isci.2024.111569↗
  18. A phase 2 trial of CXCR4 antagonism and PD1 inhibition in metastatic pancreatic adenocarcinoma reveals recruitment of T cells but also immunosuppressive macrop… Co-author DOI 10.1080/2162402x.2025.2543614↗
  19. A Phase II Study of Neoadjuvant GVAX and Cyclophosphamide Combined with Nivolumab and SBRT Followed by Surgery in Borderline Resectable Pancreatic Adenocarcino… Co-author DOI 10.1158/1078-0432.ccr-24-3403↗
  20. PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Panc… Last author DOI 10.1200/jco-25-00436↗
  21. Erratum: PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metast… Last author DOI 10.1200/jco-25-02195↗
  22. EphA2-targeted alpha-particle theranostics for enhancing PDAC treatment. Co-author DOI 10.7150/thno.106948↗
  23. Entinostat in combination with nivolumab in metastatic pancreatic ductal adenocarcinoma: a phase 2 clinical trial. Co-author DOI 10.1038/s41467-024-52528-7↗
  24. Exogenous or in situ vaccination to trigger clinical responses in pancreatic cancer. First author DOI 10.1093/carcin/bgae065↗
  25. Spatial multi-omics reveal intratumoral humoral immunity niches associated with tertiary lymphoid structures in pancreatic cancer immunotherapy pathologic resp… Co-author DOI 10.1101/2024.09.22.613714↗
  26. Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances to tumor cells. Co-author DOI 10.1126/sciadv.adk1827↗
  27. Semaphorin 3D promotes pancreatic ductal adenocarcinoma progression and metastasis through macrophage reprogramming. Co-author DOI 10.1126/sciadv.adp0684↗
  28. Pancreatic cancer is feeling the heat. First author DOI 10.1136/jitc-2024-010124↗
  29. Transfer Learning Reveals Cancer-Associated Fibroblasts Are Associated with Epithelial-Mesenchymal Transition and Inflammation in Cancer Cells in Pancreatic Du… Co-author DOI 10.1158/0008-5472.can-23-1660↗
  30. Fibroblasts in the Aged Pancreas Drive Pancreatic Cancer Progression. Co-author DOI 10.1158/0008-5472.can-24-0086↗
  31. Correction: Quantitative Spatial Profiling of Immune Populations in Pancreatic Ductal Adenocarcinoma Reveals Tumor Microenvironment Heterogeneity and Prognosti… Co-author DOI 10.1158/0008-5472.can-24-2929↗
  32. Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma. Co-author DOI 10.1158/1078-0432.ccr-23-3841↗
  33. Phosphodiesterase-5 inhibition collaborates with vaccine-based immunotherapy to reprogram myeloid cells in pancreatic ductal adenocarcinoma. Co-author DOI 10.1172/jci.insight.179292↗
  34. A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with r… Co-author DOI 10.1038/s41467-023-39196-9↗
  35. Multiomics Empowers Predictive Pancreatic Cancer Immunotherapy. First author DOI 10.4049/jimmunol.2200660↗
  36. Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy. Co-author DOI 10.1016/j.ccell.2022.10.001↗
  37. Pancreatic Cancer: Pathogenesis, Screening, Diagnosis, and Treatment. Co-author DOI 10.1053/j.gastro.2022.03.056↗
  38. Inflammatory Signaling in Pancreatic Cancer Transfers Between a Single-cell RNA Sequencing Atlas and Co-Culture Co-author DOI 10.1101/2022.07.14.500096↗
  39. Quantitative Spatial Profiling of Immune Populations in Pancreatic Ductal Adenocarcinoma Reveals Tumor Microenvironment Heterogeneity and Prognostic Biomarkers. Co-author DOI 10.1158/0008-5472.can-22-1190↗
  40. Precision Medicine in Pancreatic Cancer: Patient-Derived Organoid Pharmacotyping Is a Predictive Biomarker of Clinical Treatment Response. Co-author DOI 10.1158/1078-0432.ccr-21-4165↗
  41. Pancreatic Ductal Adenocarcinoma Cortical Mechanics and Clinical Implications. Co-author DOI 10.3389/fonc.2022.809179↗
  42. Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 2013 and 2017. Co-author DOI 10.1016/j.canlet.2020.10.039↗
  43. Implantation of a neoantigen-targeted hydrogel vaccine prevents recurrence of pancreatic adenocarcinoma after incomplete resection. Last author DOI 10.1080/2162402x.2021.2001159↗
  44. Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectabl… Co-author DOI 10.1158/1078-0432.ccr-20-2974↗
  45. Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-21-1047↗
  46. IgE-Based Therapeutic Combination Enhances Antitumor Response in Preclinical Models of Pancreatic Cancer. Co-author DOI 10.1158/1535-7163.mct-21-0368↗
  47. Leukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical Outcome. Co-author DOI 10.1158/2159-8290.cd-20-0841↗
  48. Multi-omic profiling of lung and liver tumor microenvironments of metastatic pancreatic cancer reveals site-specific immune regulatory pathways. Co-author DOI 10.1186/s13059-021-02363-6↗
  49. Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future. First author DOI 10.1016/s1470-2045(19)30795-8↗
  50. The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities. First author DOI 10.1038/s41571-020-0363-5↗

Trials 1

  1. Pancreatic Adenocarcinoma Signature Stratification for Treatment Study chair NCT04469556↗

Grants 6

  1. Targeting the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer with a Neoadjuvant Platform Clinical Trial R01CA197296↗
  2. Targeting HMGA1 Tumor-Stromal Networks in Pancreatic Carcinogenesis R01CA293602↗
  3. Administrative Core P01CA247886↗
  4. Core 2: Biospecimen/Pathology Core P50CA062924↗
  5. (PQB-3) Driver gene-induced inflammation in pancreatic cancer development R01CA184926↗
  6. JHU ICMIC Program P50CA103175↗

Closest collaborators

The 25 strongest of 290 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Lei Zheng · 44 shared papers, 2 shared grants, 2011–2026 · strength 5.73
  2. Dung Thi Le · 29 shared papers, 1 shared grant, 2011–2026 · strength 3.71
  3. Daniel A. Laheru · 34 shared papers, 2011–2026 · strength 3.71
  4. Robert A. Anders · 26 shared papers, 1 shared grant, 2011–2026 · strength 3.25
  5. Elana Judith Fertig · 18 shared papers, 2020–2026 · strength 2.92
  6. Won Jin Ho · 16 shared papers, 2020–2026 · strength 2.78
  7. Richard Andrew Burkhart · 15 shared papers, 2019–2026 · strength 2.10
  8. Nilofer Saba Azad · 9 shared papers, 1 shared grant, 2017–2026 · strength 1.98
  9. Katherine M. Bever · 13 shared papers, 2013–2026 · strength 1.96
  10. Jin Peng He · 15 shared papers, 2018–2026 · strength 1.86
  11. Eric Scott Christenson · 4 shared papers, 1 shared grant, 2020–2026 · strength 1.67
  12. Hao Wang · 9 shared papers, 2022–2026 · strength 1.65
  13. Jacquelyn W. Zimmerman · 12 shared papers, 2020–2026 · strength 1.65
  14. William Reece Burns · 4 shared papers, 1 shared grant, 2021–2026 · strength 1.63
  15. Luciane Tsukamoto Kagohara · 10 shared papers, 2021–2026 · strength 1.58
  16. Christopher L. Wolfgang · 17 shared papers, 2013–2025 · strength 1.51
  17. Mark M. Yarchoan · 11 shared papers, 2017–2026 · strength 1.48
  18. Amol Kumar Narang · 11 shared papers, 2012–2026 · strength 1.44
  19. Jae Woo Lee · 7 shared papers, 2024–2026 · strength 1.43
  20. Janelle Marie Montagne · 7 shared papers, 2022–2026 · strength 1.33
  21. Dimitrios N. Sidiropoulos · 8 shared papers, 2022–2026 · strength 1.30
  22. Linda M S Resar · 1 shared grant, 2026 · strength 1.26
  23. Neeha Zaidi · 7 shared papers, 2018–2026 · strength 1.23
  24. Laura DeLong Wood · 5 shared papers, 2022–2026 · strength 1.14
  25. Jacob T. Mitchell · 7 shared papers, 2022–2026 · strength 1.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.